Why is Samrat Pharma falling/rising?

As of 15-Jul, Samrat Pharmachem Ltd's stock price is rising, currently at Rs 372.00, reflecting an increase of Rs 6.9 or 1.89%. The stock has shown a trend reversal, gaining after three consecutive days of decline, and it outperformed its sector by 0.64% today. Over the past month, the stock has risen by 7.84%, while its year-to-date performance shows a decline of 2.63%. Despite a recent drop in investor participation, indicated by a significant decrease in delivery volume, the company maintains high management efficiency with a return on capital employed (ROCE) of 27.61% and a low debt-to-EBITDA ratio of 0.44 times. The stock is trading at a fair value compared to its peers, with a price-to-book value of 1.8 and a PEG ratio of 0.1, reflecting strong profit growth of 229.2% over the past year.
In the broader market context, the stock's short-term performance has slightly outpaced the benchmark Sensex, which has declined by 1.36% over the past week compared to Samrat Pharmachem's 1.33% drop. However, the stock's year-to-date performance lags behind the Sensex, which has gained 5.67%. The overall market sentiment may be influenced by the recent decrease in foreign institutional investors' holdings, which now stand at 0%, indicating potential concerns about long-term growth prospects. Additionally, the company's flat quarterly results and low operating profit margins may contribute to cautious investor sentiment, despite the positive indicators of management efficiency and valuation.